よむ、つかう、まなぶ。
【参考資料2】 (8 ページ)
出典
公開元URL | https://www.mhlw.go.jp/stf/newpage_26881.html |
出典情報 | 厚生科学審議会 会感染症部会(第63回 8/1)《厚生労働省》 |
ページ画像
ダウンロードした画像を利用する際は「出典情報」を明記してください。
低解像度画像をダウンロード
プレーンテキスト
資料テキストはコンピュータによる自動処理で生成されており、完全に資料と一致しない場合があります。
テキストをコピーしてご利用いただく際は資料と付け合わせてご確認ください。
参考文献
•
Adler H, et al. Clinical Features and Management of Human
Monkeypox: A Retrospective Observational Study in the UK. 2022.
The Lancet Infectious Diseases. https://doi.org/10.1016/S14733099(22)00228-6.
•
Antinori A. et al.. Epidemiological, clinical and virological
characteristics of four cases of monkeypox support transmission
through sexual contact, Italy, May 2022. Euro surveill. June 2022.
•
CDC. Monkeypox.
https://www.cdc.gov/poxvirus/monkeypox/index.html
•
CDC. Progressive vaccinia in a military smallpox vaccinee - United
States, 2009. MMWR. 2009;58(19):532–536.
https://www.cdc.gov/mmwr/preview/mmwrhtml/mm5819a5.htm
•
Duque MP. et al.. Ongoing monkeypox virus outbreak, Portugal, 29
April to 23 May 2022. Euro surveill. June 2022.
•
ECDC. Risk Assessment: Monkeypox multi-country outbreak.
https://www.ecdc.europa.eu/en/publications-data/risk-assessmentmonkeypox-multi-country-outbreak. 2022a.
•
ECDC. Epidemiological update: Monkeypox outbreak. 5-11 June
2022.
https://www.ecdc.europa.eu/sites/default/files/documents/Commun
icable-disease-threats-report-11-June-2022.pdf. 2022b.
•
European Medicines Agency. Tecovirimat SIGA. First published:
January 28, 2022.
https://www.ema.europa.eu/en/medicines/human/EPAR/tecovirimatsiga.
•
Fine PE. et al. The transmission potential of monkeypox virus in
human populations. Int J Epidemiol. 1988;17(3):643-50.
•
Grosenbach DW., et al. Oral Tecovirimat for the Treatment of
Smallpox. NEJM. 2018. 379 (1): 44–53.
•
Hammerschplag Y. et al.. Monkeypox infection presenting as genital
rash, Australia, May 2022. Euro surveill. June 2022.
•
Happi C. et al.. Urgent need for a non-discriminatory and nonstigmatizing nomenclature for monkeypox virus. Virological.org 2022.
https://virological.org/t/urgent-need-for-a-non-discriminatory-andnon-stigmatizing-nomenclature-for-monkeypox-virus/853
©National Institute of Infectious Diseases, Tokyo, Japan, 2022.
8/10
•
Adler H, et al. Clinical Features and Management of Human
Monkeypox: A Retrospective Observational Study in the UK. 2022.
The Lancet Infectious Diseases. https://doi.org/10.1016/S14733099(22)00228-6.
•
Antinori A. et al.. Epidemiological, clinical and virological
characteristics of four cases of monkeypox support transmission
through sexual contact, Italy, May 2022. Euro surveill. June 2022.
•
CDC. Monkeypox.
https://www.cdc.gov/poxvirus/monkeypox/index.html
•
CDC. Progressive vaccinia in a military smallpox vaccinee - United
States, 2009. MMWR. 2009;58(19):532–536.
https://www.cdc.gov/mmwr/preview/mmwrhtml/mm5819a5.htm
•
Duque MP. et al.. Ongoing monkeypox virus outbreak, Portugal, 29
April to 23 May 2022. Euro surveill. June 2022.
•
ECDC. Risk Assessment: Monkeypox multi-country outbreak.
https://www.ecdc.europa.eu/en/publications-data/risk-assessmentmonkeypox-multi-country-outbreak. 2022a.
•
ECDC. Epidemiological update: Monkeypox outbreak. 5-11 June
2022.
https://www.ecdc.europa.eu/sites/default/files/documents/Commun
icable-disease-threats-report-11-June-2022.pdf. 2022b.
•
European Medicines Agency. Tecovirimat SIGA. First published:
January 28, 2022.
https://www.ema.europa.eu/en/medicines/human/EPAR/tecovirimatsiga.
•
Fine PE. et al. The transmission potential of monkeypox virus in
human populations. Int J Epidemiol. 1988;17(3):643-50.
•
Grosenbach DW., et al. Oral Tecovirimat for the Treatment of
Smallpox. NEJM. 2018. 379 (1): 44–53.
•
Hammerschplag Y. et al.. Monkeypox infection presenting as genital
rash, Australia, May 2022. Euro surveill. June 2022.
•
Happi C. et al.. Urgent need for a non-discriminatory and nonstigmatizing nomenclature for monkeypox virus. Virological.org 2022.
https://virological.org/t/urgent-need-for-a-non-discriminatory-andnon-stigmatizing-nomenclature-for-monkeypox-virus/853
©National Institute of Infectious Diseases, Tokyo, Japan, 2022.
8/10